Literature DB >> 28740651

Renin angiotensin system inhibitors: a panacea for heart disease?

Karim M Al-Azizi1, Kimberly A Skelding1.   

Abstract

Entities:  

Year:  2017        PMID： 28740651      PMCID： PMC5506116          DOI： 10.21037/jtd.2017.05.65

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

2.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

5.  HFSA 2010 Comprehensive Heart Failure Practice Guideline.

Authors:  JoAnn Lindenfeld; Nancy M Albert; John P Boehmer; Sean P Collins; Justin A Ezekowitz; Michael M Givertz; Stuart D Katz; Marc Klapholz; Debra K Moser; Joseph G Rogers; Randall C Starling; William G Stevenson; W H Wilson Tang; John R Teerlink; Mary N Walsh
Journal:  J Card Fail       Date:  2010-06       Impact factor: 5.712

6.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

7.  Prevalence, causes, and consequences of masked hypertension: a meta-analysis.

Authors:  Willem J Verberk; Alphons G H Kessels; Peter W de Leeuw
Journal:  Am J Hypertens       Date:  2008-06-26       Impact factor: 2.689

8.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

9.  Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group.

Authors:  L Erhardt; A MacLean; J Ilgenfritz; K Gelperin; M Blumenthal
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

Review 10.  Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.

Authors:  James J Dinicolantonio; Carl J Lavie; James H O'Keefe
Journal:  Postgrad Med       Date:  2013-07       Impact factor: 3.840
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.